Genetic Lipid Disorder

Regeneron Pharmaceuticals announced the FDA extended its approval of alirocumab as an adjunct to diet and other LDL-lowering therapies to include patients aged 8 years and older with heterozygous familial hypercholesterolemia.

In a Mendelian randomization analysis, LDL reduction associated with statin use was linked to elevated odds of type 2 diabetes, but not with other pleiotropic effects.

PHILADELPHIA — Patients with heterozygous familial hypercholesterolemia who were treated with inclisiran had reductions in LDL at 510 days and at an average of the period between 90 days and 540 days independent of their underlying genotype, according to results of the ORION-9 trial presented at the American Heart Association Scientific Sessions.